Document Detail

Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression.
MedLine Citation:
PMID:  12051876     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The purpose of this study was to evaluate vascular endothelial growth factor (VEGF) expression in adenocarcinomas of the uterine cervix and its correlation with clinicopathologic features, angiogenesis, and expression of p53 and c-erbB-2 proteins. METHODS: Thirty-seven cases of FIGO clinical stage I and II adenocarcinoma of the uterine cervix were examined by immunohistochemical studies with anti-VEGF, anti-CD34, anti-p53, and anti-c-erbB-2 antibodies. Computerized image analysis was used to evaluate microvessel density (MVD). RESULTS: Thirty-one tumors (83.8%) were classified as VEGF positive. Six tumors (16.2%) showed p53 protein expression while 11 tumors (29.7%) expressed the c-erbB-2 protein. MVD ranged from 13.3 to 44.8, with a median value of 25.5 (26.9 +/- 7.5). Tumors expressing VEGF had a significantly higher MVD than those that did not express VEGF (P < 0.05). VEGF expression was significantly associated with c-erbB-2 protein expression (P < 0.05). The spatial distributions of both VEGF expression and c-erbB-2 expression were similar in tumor tissues. In univariate log-rank analysis, stage (P = 0.0250), lymphovascular space invasion (P = 0.0156), and MVD (P = 0.0360) were associated with shortened survival. CONCLUSION: VEGF expression plays a role in promoting angiogenesis in cervical adenocarcinomas and c-erbB-2 is likely to be involved in the up-regulation of VEGF expression.
Ji Shin Lee; Hyung Seok Kim; Jong Jae Jung; Min Cheol Lee; Chang Soo Park
Related Documents :
12213806 - P38 signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth ...
14604996 - Role of insulin receptor substrates and protein kinase c-zeta in vascular permeability ...
19805546 - Amyotrophic lateral sclerosis-linked mutant sod1 sequesters hu antigen r (hur) and tia-...
16267616 - Activation of vascular endothelial growth factor (vegf) by the er-alpha variant, erdelta3.
19380626 - A functional single-nucleotide polymorphism in the trpc6 gene promoter associated with ...
7605616 - Increased trpm-2/clusterin mrna levels during the time of retinal degeneration in mouse...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Gynecologic oncology     Volume:  85     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-07     Completed Date:  2002-07-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  469-75     Citation Subset:  IM    
Department of Pathology, Seonam University, Namwon, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / blood supply,  metabolism*
Endothelial Growth Factors / biosynthesis*
Lymphokines / biosynthesis*
Middle Aged
Neovascularization, Pathologic / metabolism*,  pathology
Receptor, erbB-2 / biosynthesis*
Survival Rate
Tumor Suppressor Protein p53 / biosynthesis*
Uterine Cervical Neoplasms / blood supply,  metabolism*,  pathology
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Reg. No./Substance:
0/Endothelial Growth Factors; 0/Lymphokines; 0/Tumor Suppressor Protein p53; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Coopera...
Next Document:  Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent c...